TIENOXOLOL

Details

Stereochemistry	RACEMIC
Molecular Formula	C21H28N2O5S
Molecular Weight	420.522
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)C1=C(OCC(O)CNC(C)(C)C)C=CC(NC(=O)C2=CC=CS2)=C1

InChI

InChIKey=PHMRLCQEIQGCHH-UHFFFAOYSA-N

InChI=1S/C21H28N2O5S/c1-5-27-20(26)16-11-14(23-19(25)18-7-6-10-29-18)8-9-17(16)28-13-15(24)12-22-21(2,3)4/h6-11,15,22,24H,5,12-13H2,1-4H3,(H,23,25)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2906898 | https://www.ncbi.nlm.nih.gov/pubmed/8098641 | https://www.ncbi.nlm.nih.gov/pubmed/22027392

Tienoxolol is a benzoic acid derivative patented by Centre d'Activite et de Recherche Pharmaceutique Industrielle Biologique et Medicale as β-sympatholytic and diuretic. Tienoxolol acts as a beta-adrenergic receptor antagonist shows potent diuretic and natriuretic activity and, besides that anti-hypertension activity in preclinical models. In clinical trials, Tienoxolol significantly and dose-dependently reduced exercise-induced tachycardia. This effect started 1 h after drug administration, peaked between 4 h and 6 h and lasted at least 12 h.

Originator

Approval Year

PubMed

Title	Date	PubMed
Evaluation of the natriuretic and beta-adrenoceptor-blocking effects of tienoxolol in normal volunteers.	1988	2906898
Analytical profile of the new diuretic beta-blocking agent tienoxolol hydrochloride.	1988 May	2901263

Patents

Sample Use Guides

In Vivo Use Guide

150 mg and 300 mg

Route of Administration: Oral

Name

Type

Language

TIENOXOLOL

Official Name

English

tienoxolol [INN]

Common Name

English

(±)-ETHYL 2-(3-(TERT-BUTYLAMINO)-2-HYDROXYPROPOXY)-5-(2-THIOPHENECARBOXAMIDO)BENZOATE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29576